申请人:Glaxo Wellcome S.A.
公开号:US06410528B1
公开(公告)日:2002-06-25
Compounds of formula (I)
and pharmaceutically acceptable salts and or metabolically labile derivatives thereof, wherein R1 represents C1-6 straight or branched chain alkyl, C1-6 straight or branched chain alkoxy, optionally substituted phenoxy, C3-6straight or branched chain alkenyloxy or C1-4 straight or branched alkoxy substituted by an optionally substituted phenyl group. C3-6 straight or branched chain alkenyl, optionally substituted phenyl, optionally substituted C3-7 cycloalkyl, C2-4 straight or branched chain alkyl substituted by (C1-4 alkoxy, C1-4 alkyl thio or halogen), C1-4 straight or branched chain alkyl substituted by (C1-4 alkoxycarbonyl, aryloxycarbonyl, cyano, optionally substituted C3-7 cycloalkyl, optionally substituted 5 or 6 membered heteroaryl, or 1 or 2 optionally substituted phenyl groups), a process for their preparation and their use in medicine.
式(I)的化合物及其药学上可接受的盐和/或代谢易变衍生物,其中R1代表C1-6直链或支链烷基,C1-6直链或支链烷氧基,可选取代的苯氧基,C3-6直链或支链烯氧基或C1-4直链或支链烷氧基被一个可选取代的苯基取代。C3-6直链或支链烯基,可选取代的苯基,可选取代的C3-7环烷基,C2-4直链或支链烷基被(C1-4烷氧基,C1-4烷基硫醚或卤素)取代,C1-4直链或支链烷基被(C1-4烷氧羰基,芳基氧羰基,氰基,可选取代的C3-7环烷基,可选取代的5或6元杂环芳基或1或2个可选取代的苯基)取代,以及它们的制备方法和在医学上的用途。